Login to Your Account



Chimerix, Omthera Set Terms; IPO Lipidity Liquidity Ahead?

By Randy Osborne
Staff Writer

Tuesday, April 2, 2013
Chimerix Inc. and Omthera Pharmaceuticals Inc. – one with an antiviral based on lipid delivery, the other with a lipid-lowering therapy – established terms for their initial public offerings (IPOs), raising investor hopes for a debut like that experienced last month by Enanta Pharmaceuticals Inc., but whether the fabled "window" will open for biotech firms this year remains in question.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription